Is the FDA’s decision to delay Sarepta drug decision good or bad? Nobody really knows By: MarketWatch May 25, 2016 at 14:52 PM EDT Eteplirsen, if approved, would be the only treatment for the rare disease Duchenne muscular dystrophy. Read More >> Related Stocks: Biomarin Pharmaceuticals Ptc Therapeutics Sarepta Therapeutics